Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 9Recruiting 8Terminated 6Withdrawn 2Unknown 2Suspended 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 4Docetaxel 3pembrolizumab 2Nivolumab 2Etoposide 2Carboplatin 2osimertinib 1icotinib 1famitinib 1durvalumab 1decitabine and cedazuridine drug combination 1dabrafenib 1cemiplimab 1alirocumab 1aldesleukin 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Radionuclide Imaging 1Radiation 1Prednisone 1Positron-Emission Tomography 1Platinum 1Pemetrexed 1Panitumumab 1Paclitaxel 1Monatide (IMS 3015) 1Methods 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × aldesleukin × Thoracic × Clear all
NCT03970382 2022-08-18

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

PACT Pharma, Inc.

Phase 1 Suspended
21 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡